Goldsmith Mark A sells $19.1M of RVMDGoldsmith Mark A 内部减持 RVMD $19.1M

The Insider Sale

GOLDSMITH MARK A, a director and officer of Revolution Medicines, sold 91,254 shares of RVMD common stock via open-market transactions on August 21, 2026, at a per-share price of $209.09 for total proceeds of $19,080,308. The corresponding Form 4 filing was submitted to the U.S. SEC on August 25, 2026. The total transaction value equals 0.042% of RVMD’s $44.9 billion market capitalization at the time.

Market Signal Context

This is not a routine small-scale insider sale: as a director and officer, the filer’s $19.1 million open-market disposition represents a material adjustment to their personal holdings, distinct from typical post-award stock option exercise sales. The transaction sends a clear signal of active personal portfolio reallocation by a senior company insider.

Cross-Reference Check

On the same August 25, 2026 filing date, the SEC also disclosed multiple Form 4 transactions from Jeff Cislini, the company’s General Counsel, who completed cumulative open-market sales of over 103,000 shares for total proceeds exceeding $17 million. Additionally, RVMD’s analyst rating distribution has remained unchanged since June 2026, with 4 strong buy, 17 buy, and 1 hold ratings.

Follow-Up Markers and Signal Limits

This Form 4 filing only documents the completed open-market trade, and does not confirm the specific motivation for the sale, nor does it indicate whether the transaction was executed under a pre-arranged 10b5-1 plan. The disclosure also does not provide insight into the company’s future performance or stock price trajectory. Investors should monitor subsequent insider transaction filings and institutional holding updates for additional context.